Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 190,921,904
  • Shares Outstanding, K 2,374,060
  • Annual Sales, $ 49,436 M
  • Annual Income, $ 6,712 M
  • 36-Month Beta 0.77
  • Price/Sales 3.92
  • Price/Cash Flow 16.80
  • Price/Book 2.81

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.06 +9.76%
on 04/24/17
81.94 -0.79%
on 05/16/17
+7.89 (+10.75%)
since 04/21/17
3-Month
72.67 +11.86%
on 04/19/17
81.94 -0.79%
on 05/16/17
+4.44 (+5.78%)
since 02/22/17
52-Week
66.93 +21.46%
on 12/08/16
83.58 -2.74%
on 07/22/16
+5.50 (+7.26%)
since 05/20/16

Most Recent Stories

More News
Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion

Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.

MRK : 64.04 (+0.41%)
LLY : 76.98 (-1.05%)
NVS : 81.29 (+1.08%)
GSK : 43.30 (-0.69%)
Look for Shares of Novartis to Potentially Pullback after Yesterday's 1.39% Rise

Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $81.25 to a high of $81.79. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $81.45 on...

NVS : 81.29 (+1.08%)
Look for Shares of Novartis to Potentially Pullback after Yesterday's 1.39% Rise

Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $81.25 to a high of $81.79. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $81.45 on...

NVS : 81.29 (+1.08%)
Telemedicine Innovator Lemonaid Health Raises $11 Million in Series A Funding

Lemonaid Health, the simplest and fastest platform for online healthcare, today announced $11 million in new funding to support continued innovation in affordable online healthcare. The Series A funding...

NVS : 81.29 (+1.08%)
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab

Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.

AGN : 219.52 (+0.18%)
NVS : 81.29 (+1.08%)
TEVA : 29.44 (-1.47%)
AMGN : 153.02 (-2.23%)
Novartis receives positive CHMP opinion for first-line use of Zykadia(R) in ALK-positive advanced non-small cell lung cancer (NSCLC)

Novartis International AG / Novartis receives positive CHMP opinion for first-line use of Zykadia(R) in ALK-positive advanced non-small cell lung cancer (NSCLC) . Processed and transmitted by Nasdaq...

NVS : 81.29 (+1.08%)
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care

Novartis will present data from across its oncology portfolio at the upcoming 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), being held June 2-6 in Chicago; the 14th International...

NVS : 81.29 (+1.08%)
ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials

NVS : 81.29 (+1.08%)
ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials

NVS : 81.29 (+1.08%)
Watch for Novartis to Potentially Pullback After Gaining 2.44% Yesterday

Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $79.96 to a high of $80.73. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $78.88 on...

NVS : 81.29 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Support & Resistance

2nd Resistance Point 82.08
1st Resistance Point 81.69
Last Price 81.29
1st Support Level 81.00
2nd Support Level 80.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.